Lifetime costs to medicare of providing care to patients with chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 6, 2012, Pages 1146-1154

  Lafeuille, Marie Hélène ^a   Vekeman, Francis ^a   Wang, Si Tien ^b   Kerrigan, Matthew ^c   Menditto, Laura ^c   Duh, Mei Sheng ^b  

^a GROUPE D ANALYSE   (Canada)

^b ANALYSIS GROUP   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Burden of illness; Chronic lymphocytic leukemia; Cost

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGED; ARTICLE; BIRTH; CANCER RADIOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PATIENT CARE; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HEALTH CARE COSTS; HUMANS; INSURANCE CLAIM REVIEW; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEDICARE; SURVIVAL ANALYSIS; TIME FACTORS; UNITED STATES;

EID: 84861409864     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.643405     Document Type: Article

References (22)

1. American Cancer Society. Chronic lymphocytic leukemia. Available from: http://www.cancer.org/docroot/CRI/CRI-2-1x.asp? Rnav- criov&dt- 62
2. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006. [Based on November 2008 SEER data submission, posted to the SEER web site 2009.] Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975-2006/
3. Keating MJ, Chiorazzi N, Messmer B, et al. Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2003:153-175.
4. Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin ' s lymphomas. J Natl Compr Canc Netw 2010;8:288-334.
5. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206. (Pubitemid 11064396)
6. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234.
7. National Cancer Institute. General information about chronic lymphocytic leukemia. Treatment option overview. [Last Modifi ed: 05/18/2010.] Available from: http://www.cancer.gov/cancertopics/ pdq/treatment/CLL/Patient/page4
8. Stephens JM, Gramegna P, Laskin B, et al. Chronic lymphocytic leukemia: economic burden and quality of life. Am J Ther 2005;12: 460-466. (Pubitemid 41445143)
9. Kasteng F, Sobocki P, Svedman C, et al. Economic evaluations of leukemia: a review of the literature. Int J Technol Assess Health Care 2007;23:43-53. (Pubitemid 46648299)
10. Bureau of Labor Statistics. Series Id CUUR0000SAM. Available from: http://data.bls.gov/timeseries/CUUR0000SAM?output-view- pct-12mths
11. Brown ML, Riley GF, Potosky AL, et al. Obtaining long-term disease specifi c costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care 1999;37:1249-1259.
12. Lin D, Feuer F, Etzioni R, et al. Estimating medical costs from incomplete follow-up data. Biometrics 1997;53:419-434. (Pubitemid 27262208)
13. Young TA. Estimating mean total costs in the presence of censoring: a comparative assessment of methods. Pharmacoeconomics 2005;23:1229-1242. (Pubitemid 41803319)
14. Riley GF, Potosky AL, Lubitz JD, et al. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995;33:828-841.
15. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman and Hall; 1993.
16. Mason JM, Drummond MF, Bosanquet AG, et al. The DiSC assay. A cost-effective guide to treatment for chronic lymphocytic leukemia? Int J Technol Assess Health Care 1999;15:173-184. (Pubitemid 29237503)
17. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991;325:81-86.
18. Shanafelt TD, Gunderson H, Call TG. Commentary: chronic lymphocytic leukemia-the price of progress. Oncologist 2010;15:601-602.
19. Yabroff KR, Warren JL, Brown ML. Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol 2007;4:643-656. (Pubitemid 350020379)
20. Hyde C, Wake B, Bryan S, et al. Fludarabine as secondline therapy for B cell chronic lymphocytic leukaemia: a technology assessment. Health Technol Assess 2002;6:1-89.
21. Agency for Healthcare Research and Quality (AHRQ). HCUPnet, Health Care Utilization Project. Available from: http://hcupnet.ahrq.gov/HCUPnet.jsp?Id = B565049F01C4826F&Form= SelALLLISTED&JS = Y&Action = %3E%3ENext%3E%3E&-ALLLISTED = No
22. Marchetti M, Barosi G, Liberato LN. Fludarabine for chronic lymphocytic leukemia. N Engl J Med 2001;344:1166-1167.